FDA Sets Data Formatting Rules for HIV Resistance

Clinical Trials Advisor
A A
The FDA is asking sponsors of antiretroviral drugs to submit clinical trial data sets that include patient, endpoint, genotypic and phenotypic data when reporting on HIV-1 resistance in support of the drug.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00